The first participant has been enrolled in a phase 2a clinical trial investigating TP-03 as a treatment for meibomian gland dysfunction in those with Demodex mites, according to a press release from Tarsus Pharmaceuticals.
TP-03 (lotilaner ophthalmic solution 0.25%) is designed to paralyze and eradicate Demodex mites that live in the meibomian glands by selectively inhibiting the GABA-Cl channels.
There are no FDA-approved pharmacologic treatments for meibomian gland dysfunction. In two pivotal trials of more than 800 subjects with Demodex blepharitis, TP-03 has been well tolerated and met all